Shilpa Medicare Limited: Q2 FY26 - Scaling New Heights with Innovation and Strategic Expansion

Nov 22, 2025

Shilpa Medicare Ltd

SHILPAMED

Ask AI

Frequently Asked Questions

Shilpa Medicare reported its highest-ever quarterly revenue of INR 372 crores, a 7% year-on-year increase, and highest-ever EBITDA of INR 110 crores, growing 21% year-on-year. The PAT for the quarter was INR 44 crores, a 144% increase.

NorUDCA (Nor-Ursodeoxycholic Acid) is a novel, first-in-class therapy launched by Shilpa Medicare in India for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Shilpa is the first company globally to launch this product, targeting a large market of 188 million patients in India.

OERIS™ (Ondansetron Extended-Release Injection) is a novel once-weekly injection for Chemotherapy-Induced Nausea and Vomiting (CINV). Positive Phase 3 results show superior convenience and efficacy, targeting a ~USD 375 million global market by improving patient compliance and reducing treatment burden.

The company is commercializing expanded capacities for high-demand API products like UDCA and Tranexamic Acid. It plans to add another 100 metric tons capacity for Tranexamic Acid and expects the API business to continue double-digit year-on-year growth.

The Biologics division is advancing two new Novel Biologic Entities (NBEs) and its first ADC biosimilar towards Phase 1 human studies in FY27. Aflibercept, a major biosimilar, is in Phase III studies and is expected to launch in FY27.

Shilpa Medicare has partnered with Orion Corporation for rHA commercialization in Europe. Phase 3 trials are set to begin in India and the EU in FY26, with a Pre IND filing planned for the US in 2HFY26. The production technology is patented in key developed markets.

Shilpa Medicare plans to fund most of its capex programs through internal accruals, aiming to keep interest outgo stable. The company maintains a healthy Net Debt to EBITDA ratio of 1.4x, reflecting disciplined financial management.

Related Blogs

SHILPAMED

Q3 FY26

Shilpa Medicare's Stellar Q3 FY26: A Deep Dive into Record Performance and Strategic Growth

Feb 07, 2026

BLUEJET

Q3 FY26

Blue Jet Healthcare Navigates Q3 FY26 Headwinds with Strategic Investments

Feb 14, 2026

AARTIPHARM

Q3 FY26

Aarti Pharmalabs: Navigating Growth and Operational Hurdles in Q3 FY26

Feb 11, 2026

SUDEEPPHRM

Q3 FY26

Sudeep Pharma: Powering Growth with Specialty Ingredients and Battery Materials

Feb 10, 2026

JSLL

Q3 FY26

Jeena Sikho Lifecare: A Deep Dive into Q3 FY26 Performance and Strategic Vision

Feb 10, 2026

AKUMS

Q3 FY26

Akums Drugs & Pharmaceuticals Limited: A Deep Dive into Q3 FY26 Performance

Feb 15, 2026

A NOTE FROM THE FOUNDER

Hey, I'm Aaditya, founder of Multibagg AI. If you enjoyed reading this article, you've only seen a small part of what's possible with Multibagg AI. Here's what you can do next:

Aaditya AanandFounder, Multibagg AI

Shilpa Medicare Limited: Q2 FY26 - Scaling New Heights with Innovation and Strategic Expansion

Shilpa Medicare Ltd

Ask AI

Frequently Asked Questions

Ask Iris

Discovery

Portfolio

Timeline

Investor’s Suite

Screeners

Market Pulse

Deep Dive

Utility

Company